Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

CURRENT STATUS: ACCEPTED

Silje Watterdal Syversen s.w.syversen@gmail.com
Diakonhjemmet Sykehus AS
Corresponding Author
ORCiD: 0000-0003-2159-3696

Guro Løvik Goll
Diakonhjemmet Sykehus AS

Kristin Kaasen Jørgensen
Akershus Universitetssykehus HF

Inge Christoffer Olsen
Oslo universitetssykehus Ulleval

Øystein Sandanger
Oslo universitetssykehus Rikshospitalet

Johanna Elin Gehin
Oslo Universitetssykehus

David John Warren
Oslo Universitetssykehus

Joseph Sexton
Diakonhjemmet Sykehus AS

Cato Mørk
None

Jørgen Jahnsen
Akershus Universitetssykehus HF

Tore Kristian Kvien
Diakonhjemmet Sykehus AS
Abstract

Background

Infliximab (INX) and other TNF-inhibitors (TNFi) have revolutionised the treatment of several immune mediated inflammatory diseases. Still, many patients do not respond sufficiently to therapy or loose efficacy over time. The large individual variation in serum drug concentrations on standard doses and the development of anti-drug antibodies are thought to be major reasons for treatment failures. Therapeutic drug monitoring (TDM), an individualised treatment strategy based on systematic assessments of serum drug concentrations, has been proposed as a clinical tool to optimise efficacy of INX treatment. TDM seems reasonable both from a clinical and an economical point of view, but the effectiveness of this treatment strategy has not yet been demonstrated in randomised clinical trials. The NORwegian DRUg Monitoring study (NOR-DRUM) aims to assess the effectiveness of TDM, both with regard to achieve remission in patients starting INX treatment (part A) as well as to maintain disease control in patients on INX treatment (part B).

Methods

The NOR-DRUM study is a randomised, open, controlled, parallel-group, comparative, multi-centre, national, superiority, phase IV study with two separate parts, NOR-DRUM A and NOR-DRUM B. Patients with rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, ulcerative colitis, Crohn’s disease and psoriasis are included. In both study parts participants are randomised 1:1 to either TDM of infliximab (intervention group) or to standard treatment with infliximab without knowledge of drug levels or ADAAb status (control group). 400 patients starting INX therapy will be included in NOR-DRUM A. The primary outcome is remission at 30 weeks. In NOR-DRUM B, 450 patients on maintenance treatment with INX will be included. The primary endpoint is occurrence of disease
worsening during the 52 weeks study period.

Discussion

As the first trial to assess the effectiveness, safety and cost-effectiveness of TDM in patients receiving TNFi for a range of immune mediated inflammatory diseases, we hope that the NOR-DRUM study can contribute to the advancement of evidence based personalised treatment with biological medicines.

Background

Infliximab (INX) and other tumor necrosis factor inhibitors (TNFi) have revolutionised the treatment of a range of prevalent chronic immune mediated inflammatory diseases, and remission has become an achievable treatment goal. Unfortunately, more than half of the patients either do not respond sufficiently to therapy or loose efficacy over time (1-8). A failure to achieve or maintain disease control has a major impact on patients’ quality of life and puts the individual at risk of developing irreversible organ damage and disability. Loss of clinical efficacy may be due to subtherapeutic drug levels (9-11). Methods for measurement of serum drug concentrations of INX and other biological drugs have recently become available for use in clinical practice. In patients on standard doses of INX, significant inter-individual variations in serum drug levels, ranging from undetectable to significantly above the presumed therapeutic range, have been revealed (9-11). One major reason for this inter-individual variation is development of anti-drug antibodies (ADAb) (9-11). Antibody-based biological drugs, being large, complex and allogenic proteins, can elicit an immune response resulting in production of ADAb. The chimeric mouse/human structure of INX might explain the high occurrence of ADAb (10-60% across studies) compared to other TNF-inhibitors (9-11). The initial studies of the INX biosimilar CT-P13 indicate a similar immunogenicity profile to the innovator INX, and ADAb to INX are cross-reactive to CT-P13 (12-14). Low levels of ADAb may be transient, but high levels
influence the pharmacokinetics of the drug and decrease serum concentrations (9-11). The presence of ADAb may also be associated with serious side effects of INX such as hypersensitivity reactions (9-11).

In an effort to optimise efficacy, clinicians often intensify the INX treatment by increasing the dose or decreasing the interval between infusions (8, 15, 16). Large cohort studies show that up to 50% of patients have had one or more dose escalations within the first year of treatment (8, 15, 16). The effectiveness of such empiric dose escalation is probably minimal in patients with ADAb or with already high drug levels, explaining the conflicting results regarding the effectiveness of empiric dose escalation (15, 16). The economic consequences of increasing the dose are considerable related to the high cost of INX.

With this background, therapeutic drug monitoring (TDM), an individualised treatment strategy based on systematic assessments of serum drug concentrations, has been proposed as a clinical tool to optimise efficacy, patient safety and cost effectiveness of TNFi (17). A treatment strategy based on TDM may improve INX therapy by:

1. minimising undertreatment, which might lead to lack of response, loss of response, and possibly also predispose to ADAb production
2. reducing overtreatment, which predisposes patients to side effects and increase cost for payers
3. allowing the early identification of ADAb development thus, enabling the detection of treatment failures prior to a clinical flare, discontinuation of ineffective treatment and prevention of hypersensitivity reactions
4. aiding in treatment decisions in patients with treatment failures (i.e. dose increase in patients with low levels, switch therapy to another TNFi in case of ADAb development or to treatment with a biologic with a different mode of action in the case of
treatment failure despite adequate INX levels)

Although the exact therapeutic window of INX has not been clearly defined, a trough level above 3 µg/ml during maintenance therapy and above 20 µg/ml during the induction period, has been associated with improved clinical outcomes in several observational studies and post hoc analyses of clinical trials across different diseases (18-27). TDM has gained great interest within gastroenterology over the last years (28-30) and has now also been put on the research agenda in international rheumatology (31). The European League Against Rheumatism (EULAR) has recently established a Task Force named “Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatology”, aiming to further develop the research agenda within this field. Supported by observational data (18-27) and clinical experience, TDM of INX treatment has already been implemented in clinical practice in some Norwegian and other European centres with available methodology and special interest in immunogenicity. Reports indicating clinical effectiveness of TDM in a randomised controlled setting are, however, limited to two studies of patients with inflammatory bowel disease (IBD) (24, 32). In the TAXIT-trial (Trough Level Adapted Infliximab Treatment study) all patients underwent INX dose optimisation based on trough level 3-7 µg/ml prior to randomisation, which significantly increased the percentage of Crohn’s disease (CD) patients in remission from 64% to 92% (24). After dose optimisation, continued TDM was not superior to clinically based dosing for achieving remission after 1 year, but was associated with fewer flares during the course of treatment (24). TDM of INX treatment was also evaluated in the TAILORIX (A Randomised Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn’s Disease) randomised controlled trial (32). In this trial patients were randomised to either an algorithm based on clinical symptoms, biomarkers and TDM or to symptom-based management. No differences in the proportion of patients in steroid-free clinical and
endoscopic remission (primary endpoint) were shown.

Data from randomised controlled trials to support guidelines and recommendations for implementation of TDM in standard care of patients on treatment with INX and other biological drugs are highly needed in an era of increasing use of therapeutic monoclonal antibodies. The main aim of the NORwegian DRUg Monitoring study (NOR-DRUM) is to assess the effectiveness of TDM, both in achieving remission in patients starting INX treatment (part A) as well as in maintaining disease control in patients on INX treatment (part B).

Methods

Overview of study design

The NOR-DRUM study is a randomised, controlled, parallel-group, open, comparative, multi-centre, national, superiority, phase IV study with two separate parts (NOR-DRUM A and NOR-DRUM B) comparing TDM of INX treatment to standard INX treatment. The study design is outlined in Figure 1. Schedule of enrolment, interventions and assessments are given in Figure 2 (NOR-DRUM A) and Figure 3 (NOR-DRUM B). The Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) checklist detailing the items in this clinical trial protocol is provided as Additional file 1.

Study setting and population

All Norwegian hospitals treating patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA), ulcerative colitis (UC), Crohn’s disease (CD) or psoriasis (Ps) were invited to participate. The study is conducted at 21 study centres distributed across all four Norwegian health regions. After initiation of the sites, potential study participants (patients who are either starting INX or who have been treated with INX for minimum 30 weeks or maximum 3 years) are informed about the study by their treating
physician. After signing the informed consent, they are screened and if eligible included in the study by study personnel. Inclusion- and exclusion criteria are shown in Table 1. Recruitment of patients is taking place in a competitive manner until 400 patients have been included in NOR-DRUM A and 450 patients have been included in NOR-DRUM B.

Table 1 Eligibility criteria

Randomisation procedures and allocation

Eligible patients are assigned a unique patient identification number. In NOR-DRUM A, patients are allocated in a 1:1 ratio between intervention and control, using a computer randomisation procedure stratifying by diagnosis (RA, SpA, PsA, UC, CD, Ps). The randomisation is blocked within each stratum. In NOR-DRUM B, patients are allocated in a 1:1 ratio between intervention and control, using a computer randomisation procedure stratifying by diagnosis (RA, SpA, PsA, UC, CD, Ps) and 1) by study arm (intervention or control) if the patient originates from NOR-DRUM A or 2) by prior or no prior TDM in the clinic (defined as one or more assessments of serum drug level during the last 3 infusions) if the patient originates from NOR-DRUM B. The randomisation is blocked within each stratum. The computer-generated randomised allocation sequence is imported into the electronic Case Report Form (eCRF) system and made available to site personnel. The allocation is not available until the patient has signed the informed consent form and deemed eligible to participate in the study. Authorised personnel will only know the allocation of included patients, but not for future patients. Details of block size and allocation sequence generation are kept unavailable to those who enrol patients or assign treatment.

Intervention

In both study parts (A and B) patients are randomised to either:
1. Administration of INX according to a treatment strategy based on TDM and assessments of ADAmb (intervention group)

2. Administration of INX according to standard clinical care, without knowledge of drug levels or ADAmb status (control group)

The treatment strategy in the intervention group is outlined in Figure 4 and 5. At each visit/infusion, s-INX and ADAmb are assessed, and in the intervention group the levels are reported back to the investigators who will adjust the dose or infusion interval according to the strategy (Figure 4 and 5). During the first infusions (up to and including week 14), the dose is adjusted by decreasing the infusion interval (Figure 4). After week 14, both increasing and decreasing the INX dose or intervals to reach the target range of 3-8 µg/ml are permitted by the algorithm (Figure 5).

The randomised treatment strategy is continued for the whole study period (38 (+/-4) weeks in NOR-DRUM A and 52 (+/-4) weeks in NOR-DRUM B) with study visits at each scheduled INX infusion. After 38 weeks in NOR-DRUM A, patients who are still on INX are included and re-randomised in NOR-DRUM B. Patients who for any reason (lack of efficacy, side effects or other) are switched to another treatment during the study, will still be followed with study visits according to the intentional infusion intervals and remain in the allocated group. Immunosuppressive concomitant treatments initiated before inclusion in the study are continued. To improve compliance to the strategy in the intervention group, an interactive eCRF with guidelines for INX dosing based on INX levels have been developed (Viedoc 4™, Uppsala, Sweden).

In NOR-DRUM A, improvement is assessed after 3 months (Week 14 visit), for which a separate algorithm is used (Figure 4). Improvement is defined as: RA and PsA: a decrease in Disease Activity Score using 28 joints (DAS 28-SR) of ≥1.2 from baseline; SpA: a decrease in Ankylosing Spondylitis Disease Activity-C-reactive protein Score (ASDAS-CRP)
of $\geq 1.1$ from baseline; UC: a decrease in the partial Mayo score of $\geq 3$ from baseline or a partial Mayo score of 0; CD: a decrease in the Harvey-Bradshaw (HBI) of $\geq 4$ from baseline; Ps: Psoriasis Area and Severity Index (PASI) 50 (a 50% reduction in the PASI score from baseline); Investigator and patient consensus on improvement: If a patient does not fulfil the formal definition, but both the patient and the investigator agree that the patient has improved this should be considered as improvement but recorded separately in the CRF.

Patients have the right to withdraw from the study at any time for any reason. In the case that a patient decides to do so, they will be asked if they can still be contacted for further information, so that a final evaluation can be made with an explanation for the withdrawal, including assessment of possible adverse events.

The investigator may discontinue the patient from further study participation if such participation will put the patient at risk of medical injury or there has been a major protocol violation.

Outcomes

Primary outcomes

The primary outcome in NOR-DRUM A is remission at week 30, while the primary outcome in NOR-DRUM B is sustained disease control without disease worsening throughout the study period. Remission and disease worsening are defined as disease specific activity scores as summarised in Table 2.

Table 2 Definition of primary outcomes

Additionally, disease worsening can be recorded based on patient and investigator consensus on disease worsening: If a patient does not fulfil the formal definition, but experiences a clinically significant worsening according to both the investigator and patient that leads to a major change in treatment (i.e. switching from INX to another
immunosuppressant/Disease-Modifying Anti-Rheumatic Drug (DMARD), adding a immunosuppressant/DMARD, increasing the dose of a concomitant immunosuppressant/DMARD, adding systemic glucocorticoids (po., iv. or im.), receiving more than one i.a. glucocorticoid injection at one visit or increasing INX for clinical reasons) this should be considered as a disease worsening but be recorded separately in the eCRF.

**Secondary and exploratory outcomes**

In NOR-DRUM A, secondary outcomes include generic outcomes; time to sustained remission (a status of remission on all consecutive visits following the initial obtained remission), patient’s and physician’s global assessment of disease activity, biochemical parameters of disease activity, occurrence of ADAb, occurrence of and reason for drug discontinuation, safety and cost effectiveness, utility and quality of life in addition to disease specific activity composite scores assessed at all visits; RA: DAS28, Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), Rheumatoid Arthritis Impact of Disease (RAID), Modified Health Assessment Questionnaire (MHAQ), PsA: DAS28, Psoriatic Arthritis Impact of Disease (PsAID) score-9, Disease Activity Psoriatic Arthritis (DAPSA) score, MHAQ, Dermatology Life Quality Index (DLQI), SpA: ASDAS, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), MHAQ, UC: Partial Mayo Score, Inflammatory Bowel Disease Questionnaire (IBDQ), CD: HBI, IBDQ, Ps: PASI, DLQI. In NOR-DRUM B secondary outcomes include generic outcomes; time to disease worsening, patient and physician global assessment of disease activity, biochemical parameters of disease activity, occurrence of ADAb, occurrence of and reason for drug discontinuation, safety and cost effectiveness, utility and quality of life in addition to disease specific activity scores assessed at all visits as listed above for NOR-DRUM A.

**Study schedule and assessments**
The schedule of enrolment, interventions and assessments in NOR-DRUM A and NOR-DRUM B are depicted in the SPIRIT figures 2 and 3. The study visits are carried out according to the patient’s INX treatment schedule and the number of visits varies depending on the infusion intervals. Extra study visits are arranged at the request of the patient and/or the investigator. If INX treatment is terminated, patients are assessed according to the original infusion plan (every 8. weeks). The assessments performed at each visit are shown in figure 2 and 3. The primary outcome in NOR-DRUM A (remission) will be recorded at the week 30 (+/- 2 weeks) visit. In NOR-DRUM B the primary outcome (occurrence of disease worsening) is recorded at every visit during the 12 month follow-up period. If the patients perceive increased disease activity, a non-scheduled visit will be arranged within one week in order to identify occurrence of disease worsening.

**Laboratory assessments**

Blood samples are collected at all visits prior to the infusion. Hematology and clinical chemistry parameters, as well as acute phase reactants and faecal calprotectin in IBD-patients, are analysed at the local hospital laboratory or referred to other laboratories according to local practice. Samples for bio banking and measurement of serum INX-levels and ADAAb are sent to the Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet. Serum INX-levels (trough) and ADAAb will be measured using in-house assays automated on the AutoDELFIA immunoassay platform (PerkinElmer, Waltham, MA) (33). Laboratory data are stored in the laboratory information system, and results for patients in the intervention group are reported to the local investigator. All results will be transferred to the principal investigator upon completion of the study.

**Statistics**

**Sample size and power considerations**
Sample sizes are determined for each of the two study parts separately. NOR-DRUM A:
Under the assumption of an (absolute) increase in remission rate of 15% (from 40 to 55%)
358 completed patients are needed in order to reject the null hypothesis at a 5%
significance level with 80% power. Adjusting for possible drop-outs, we plan to randomise
400 patients.
NOR-DRUM B: Under the assumption of an (absolute) decrease in proportion of patients
with disease worsening of 12.5% (from 30 to 17.5%) 414 completed patients are needed in
order to reject the null hypothesis at a 5% significance level with 85% power. Adjusting for
possible drop-outs, we plan to randomise 450 patients.

Statistical plan
Separate statistical analysis plans (SAP) for each study part will provide further details on
the planned statistical analyses. The SAPs will be finalised, signed and dated prior to data
lock for each of the parts.

Populations
The primary outcomes of both study parts will be analysed in the intention to treat (ITT)
population. The ITT population consists of all randomised patients who have been exposed
to the intervention (completed first infusion in NOR-DRUM B or completed second infusion
in NOR-DRUM A). The per-protocol (PP) population will in each of the two study parts
consist of all randomised patients who sufficiently comply with the protocol. Criteria for
inclusion in the PP population will be specified in the SAP, and the final criteria will be
defined prior to database lock. The safety population consist of all patients who have been
exposed to the intervention (same definition as the ITT population).

Statistical model
The primary variables will be analysed using logistic regression models with strategy
treatment group as primary explanatory variable, adjusted for stratification factors used
at randomisation. Although this is a multicentre study, study site will not be used for stratification or adjustment in the analysis due to anticipated small sample sizes within site. However, sensitivity analyses will be performed to assess the impact of site on the study conclusions. Other pre-specified covariates included in sensitivity analyses include age, use of disease-specific co-medication (methotrexate, azathioprine or similar) and levels of ADAAb at baseline. The SAP will detail these procedures, as well as alternative and further supportive evaluations, such as analyses including unbalanced baseline predictors or modifications of the logistic regression model in case validity assumptions are not met.

Primary analyses

The primary analysis will be performed on the ITT population. There will be two primary hypotheses tested in this study, one for each of the two parts (NOR-DRUM A and B). No adjustment for multiplicity will be made, since each part will be regarded as answering an independent research question.

In NOR-DRUM A the statistical hypothesis tested is (superiority test): Null hypothesis: There is no difference in the proportion of patients in remission at week 30 between the intervention and control group. Alternative hypothesis: There is a difference in the proportion of patients in remission at week 30 between the intervention and control group. The hypothesis test will be evaluated by logistic regression analysis. A conclusion of superiority of either of the treatment strategies will be made if the null hypothesis is rejected at the 5% significance level. If the study fails to reject the primary null hypothesis, non-inferiority of TDM vs standard care will be assessed using a non-inferiority margin of 15%. Non-inferiority implies that the 95% confidence limits of the estimated adjusted risk difference of disease worsening lies fully within a non-inferiority margin of 15%.

In NOR-DRUM B the statistical hypothesis tested is (superiority test): Null hypothesis:
There is no difference in proportion of patients in sustained disease control throughout the study period without disease worsening between the intervention and control group.  
Alternative hypothesis: There is a difference in proportion of patients in sustained disease control throughout the study period without disease worsening between the intervention and control group. The primary variable will be evaluated by the p-value of the hypothesis test from the logistic regression analysis. A conclusion of superiority of any of the treatment strategies will be made if the null hypothesis is rejected on a significance level of 5%. If the study fails to reject the primary null hypothesis, non-inferiority of TDM vs standard care will be assessed in the PP population, also using a 15% non-inferiority margin. Non-inferiority implies that the 95% confidence limits of the estimated adjusted risk difference of disease worsening lies fully within a non-inferiority margin of 15%.

Secondary analyses

Between-group comparisons will be performed for the primary endpoints on secondary populations in addition to secondary efficacy endpoints on both efficacy populations. The between-group comparisons for secondary variables will be tested as for the primary variable where applicable and additional analyses will be performed based on the following methods (but not limited to); repeated measures mixed models or appropriate non-parametric alternatives (continuous variables), logistic regression (possibly adjusting for within-subject dependencies by mixed model approaches) or chi-square/Mantel-Haenszel test for binary response variables, Kaplan-Meier method (Time-to-event variables) and comparisons between the two groups will be performed using the log rank test, Cox regression analyses and/or appropriate parametric models such as the Weibull model. Unless otherwise specified, all statistical hypotheses will be tested as the primary variable, i.e. with an assessment of superiority based on the p-value of the group differences. Methods to handle missing data may include complete case analyses, last
observation carried forward, worst case/best case imputation and multiple imputation techniques. For the primary analyses, worst case imputation will be used for missing observations. Further details on missing data will be given in the SAP.

Safety analyses will be descriptive and presented as summary tables by treatment group and (if applicable) by visit. Patient reported outcome measures (PROMs) and disability will be assessed using Short Form (36) Health Survey (SF-36) (generic), EuroQol 5 Dimensions (EQ-5D) (generic), MHAQ (RA, PsA, SpA), IBDQ (IBD) and DLQI (Ps). These scores will be summarised by descriptive summary tables at baseline and over time, and at the end of study. Missing data at end of study will be replaced by the last valid post-baseline assessment. We will perform subgroup analyses according to diagnoses groups (RA, SpA, PsA, UC, CD, Ps) on the appropriate primary and secondary variables using methods described above. Other exploratory subgroup analyses of primary, secondary and exploratory efficacy variables may be performed if appropriate. The decision to include such analyses will be made on basis of the collected data. Health economic analyses appropriate analyses as estimating the number of quality-adjusted-life-years (QALYs) obtained during the study period. For each patient we will estimate one year costs based on register data for utilisation of health care and the unit costs. The mean week QALYs and cost in the two treatment arms will be used to estimate an incremental cost-effectiveness ratio for all patients and according to diagnostic group.

Adverse events

Any adverse event (AE) encountered during the clinical study is reported in the eCRF. If the patient has experienced AE (s), the investigator records the following information in the eCRF: The nature of the event is described by the investigator in precise standard medical terminology. The duration of the event is described in terms of event onset date and event ended date. The intensity of the adverse event is graded as mild, moderate,
severe, life threatening or death. The causal relationship of the event to the study medication is assessed as unrelated, unlikely, possible, probable or definite. Events which are definitely due to disease progression are not reported as an AE. Serious adverse events (SAEs) are reported to the central study coordinating team.

Data registration and monitoring

A web-based eCRF software solution is used to collect study data (Viedoc 4™, Uppsala, Sweden). The Principal Investigator at each study centre is responsible for assuring that data entered into the eCRF is complete, accurate, and that entry is performed in a timely manner. The electronic signature of the investigator will attest the accuracy of the data on each CRF. If any assessments are omitted, the reason for such omissions will be noted on the CRFs. Corrections, with the reason for the corrections will also be recorded. A complete list of authorised study personnel will be maintained during the study, and only study personnel authorised by the principal investigator or coordinating investigator will be allowed to sign the eCRF. Protocol, protocol amendments, investigator’s brochure, informed consent and all study-related documents have been reviewed by an institutional review board and a GCP (Good Clinical Practice) certified person. All participating centres will be monitored during and after the trial by GCP-trained personnel in order to ensure compliance with GCP, the protocol, and all other applicable regulations.

Publications

Upon study completion and finalisation of the study report the results of this study will be submitted for publication and posted in a publicly assessable database of clinical study results.

The results of this study will also be submitted to the Ethics Committee according to national regulations. All personnel who according to the ICMJE recommendations have
contributed significantly in the planning and performance of the study will be included in the list of authors. Authorship will be based on scientific contribution and enrolment.

Discussion

The clinical role of TDM of TNFi and other biopharmaceuticals used for immune mediated inflammatory disorders is still debated. Currently, implementation is based on clinical experience and observational studies, since only a few clinical trials have been conducted (24, 32). To our knowledge, the NOR-DRUM study is the first randomised controlled trial assessing the effectiveness and safety of TDM in INX treatment across a range of immune mediated inflammatory disorders.

NOR-DRUM is investigator initiated and fully funded by a joint grant from the four Norwegian regional health authorities. The study is conducted as a shared effort by Norwegian rheumatologists, gastroenterologists and dermatologists, and 21 study centres across Norway participate in the data collection. Norway is particularly well suited to conduct this large scale trial on TDM. Due to a tender based prescription system and to the early implementation of biosimilars, INX has for the last years been the preferred TNFi for Norwegian clinicians treating patients with immune mediated inflammatory diseases. Additionally, the recent completion of the large NOR-SWITCH trial (33, 34) has established a strong research collaboration between the different specialities using TNFi and good logistics for conducting clinical trials at the infusion units nationwide. Finally, the Department of Medical Biochemistry at Oslo University Hospital is a non-commercial, high-capability, facility for antibody analyses and has developed assays for serum drug measurement of biological drugs and antidrug antibodies while performing these analyses on a self-cost basis.
The implementation of TDM depends on a validated therapeutic target range. The treatment algorithms in NOR-DRUM are based on an extensive literature review and expert opinions. They have been developed through a series of meetings in the project group consisting of national leading experts in this field (both clinicians experienced with TDM and laboratory physicians) and with additional input from international key experts in the scientific advisory board. The therapeutic level of INX is not definitely known for all the diseases, but there are strong indications that the lower limit is close to 3µg/ml (20-24, 26). According to the literature review and expert opinion, the upper limit has been set to 8µg/ml. The borders of the proposed therapeutic range, the yellow zones in Figure 4 and 5, allow for some clinical considerations regarding the INX dosing. In the induction phase, the limits of 20µg/ml at infusion 2 and 15µg/ml at infusion 3 are based on clinical observations and previous literature (27, 35). There is still no consensus whether dose adjustments or interval changes are the most effective and cost effective way to increase or decrease the INX dose. Initial pharmacokinetic modelling suggested that a higher trough level could be achieved using less INX over time by shortening the interval instead of increasing the dose (36). More recent studies suggest that a dose of i.e. 10mg/kg every 8 weeks are probably equal to 5 mg/kg every 4 weeks, (37) and halving the infusion intervals are not superior to increasing dose when it comes to both effect and drug costs (38). The proposed algorithms allows for both options, but due to lower drug costs in recent years, patient convenience and high costs of running infusion units, the preferred option is dose increase by increasing each infusion dose and dose decrease by increasing the infusion interval.

The NOR-DRUM study has an open-label design where both the investigator and the patient know to which study-arm the patient belongs. Blinding of the study participants has not been possible as the participants in the intervention group are experiencing
changes in the dosing intervals based on serum drug levels. Feasible data collection within the frame of daily clinical practice at a large number of study centres has been important in this trial. Thus, it has not been possible to blind study personnel. We cannot exclude that the open-label design may affect the primary endpoint as this is partly based on PROs and for some parameters the judgement of the investigators i.e. joint counts in RA and PsA and PASI score in Ps and PsA. Blinding of study personnel would have required two sets of personnel at each site, making the study unfeasible. Dose adjustments may occur in both arms though it is based on the study algorithm in the intervention arm only. Patients in both arms are treated with the same biological agent with standardised frequency of follow-up and the same management of complications. Sensitivity analyses will be performed to compare results of subjective and objective outcome measures. The study is not powered to demonstrate superiority within each diagnostic group as inclusion of the required number of patients is not achievable in Norway within a reasonable timeframe and funding resources. As such, the primary endpoint is designed to evaluate the occurrence of remission (NOR-DRUM A) or disease worsening (NOR-DRUM B) across diseases. The choice of these generic endpoints are based on well-established measures of disease activity and predefined cut-offs for disease state and change for each diagnosis. The feasibility of these outcomes in a clinical-trial setting was tested successfully in the NOR-SWITCH trial (33, 34).

In addition to assessing the effectiveness of TDM (the primary objective), we will also address safety i.e. occurrence of infusion reactions and infections, and the effect of TDM on cost-effectiveness. Important exploratory objectives are prediction of immunogenicity i.e. by genetic testing.

This large national multicentre trial assessing the effectiveness, safety and cost-effectiveness of TDM in INX treated patients is expected to provide valuable information
that will hopefully contribute to a reduction in the burden of disease in a range of common chronic diseases with a potentially disabling disease course, as well as a reduction of the high expenses related to biological therapy. The impact of TDM of biological therapy is currently a topic of great interest to clinicians both nationally and internationally. As the first trial to assess the effect of TDM in patients with a wide range of immune mediated inflammatory diseases on treatment with a TNF inhibitor, we hope the NOR-DRUM study will contribute to evidence-based implementation of TDM in standard care of patients treated with INX and other biological drugs.

TRIAL STATUS

Protocol version 1.2; December 2017

Recruitment started in January 2017 and the trial is still recruiting. Recruitment is planned to end December 2019.

Abbreviations
| Abbreviation or special term | Explanation |
|------------------------------|-------------|
| ADAb | Anti-drug antibody(ies) |
| AE | Adverse Event |
| ASDAS | Ankylosing Spondylitis Disease Activity Score |
| BASDAI | Bath Ankylosing Spondylitis Disease Activity Index |
| CD | Crohn’s disease |
| CDAI | Clinical Disease Activity Index |
| CRF | Case Report Form (electronic/paper) |
| DAS28 | Disease Activity Score using 28 joints |
| DLQI | Dermatology Life Quality Index |
| DMARD | Disease-Modifying Anti-Rheumatic Drugs |
| eCRF | electronic Case Report Form |
| EULAR | European League Against Rheumatism |
| EQ-5D | EuroQol 5 dimensions |
| HBI | Harvey-Bradshaw Index |
| IBD | Inflammatory bowel diseases |
| IBDQ | Inflammatory Bowel Disease Questionnaire |
| IJD | Inflammatory Joint Diseases |
| INX | Infliximab |
| MHAQ | Modified Health Assessment Questionnaire |
| PASI | Psoriasis Area and Severity Index |
| PGA | Patient Global Assessment of Disease Activity |
| PhGA | Physician Global Assessment of Disease Activity |
| PRO | Patient reported outcome |
| PsA | Psoriatic arthritis |
| PsAID | Psoriatic Arthritis Impact of Disease |
| QALY | Quality-adjusted life year |
| RA | Rheumatoid arthritis |
| RAID | Rheumatoid Arthritis Impact of Disease |
| SAE | Serious Adverse Event |
| SDAI | Simplified Disease Activity Index |
| SF-36 | Short Form (36) Health Survey |
| SpA | Spondyloarthritis |
| SPIRIT | The Standard Protocol Items: Recommendation for Intervventional Trials |
| TDM | Therapeutic drug monitoring |
| TNF | Tumor necrosis factor |
| TNFi | TNF inhibitor |
| UC | Ulcerative colitis |
| WPAI:GH | Work Productivity and Activity Impairment Questionnaire: General Health |

**Declarations**

**Ethics approval and consent to participate**

The NOR-DRUM study will be carried out in accordance with the declaration of Helsinki and the protocol has been approved by the Norwegian Regional Committees for Medical and Health Research Ethics ID 2016/1231. All patients will receive oral and written information
and give their written informed consent before screening. Patients can withdraw their consent at any time. The study protocol, including the patient information and informed consent form to be used, has been approved by the regional ethics committee before enrolment of any patients into the study.

Consent for publication

Not applicable

Availability of data and materials

The full trial protocol (version 1.2 date 12.12.17) is available from the corresponding author on request. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Competing interests

SWS reports personal fees for speaking from Roche.

GLG reports personal fees from AbbVie, Eli Lilly, Novartis, Pfizer, Roche, Sandoz, Orion Pharma, Celltrion and Boehringer Ingelheim.

KKJ reports personal fees from Intercept, Norgine and Celltrion.

ICJ reports personal fees from Pfizer.

ØS declares that he has no competing interests.

JG reports personal fees for speaking from Roche.

DJW declares that he has no competing interests.

JS declares that he has no competing interests.

CM reports fees for speaking and/or consulting from Novartis, LEO Pharma, ACO, Petrified Nordic, Abbvie, Galderma Nordic, Celgene

Tore K Kvien reports fees for speaking and/or consulting from AbbVie, Biogen, Celltrion, Egis, Eli Lilly, Hikma, MSD, Mylan, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche,
Sandoz, Sanofi and UCB and has received research funding to Diakonhjemmet Hospital from AbbVie, BMS, MSD, Pfizer, Roche and UCB.

JJ has served as a speaker, consultant or advisory board member for AbbVie, Astro Pharma, Boehringer Ingelheim, BMS, Celltrion, Ferring, Hikma, Janssen, Meda, MSD, Napp Pharma, Norgine, Novartis, Orion Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Tillotts and Sandoz

NB reports personal fees from Orion Pharma, Roche, Napp Pharmaceuticals, Pfizer and Takeda.

EAH reports fees for speaking and/or consulting from AbbVie, Eli Lilly, Pfizer, Roche, Celgene, Janssen and UCB and has received research funding to Diakonhjemmet Hospital from AbbVie, MSD, Pfizer, Roche and UCB.

Funding

The NOR-DRUM study has received funding from Norwegian Regional Health Authorities (inter-regional grants), South-Eastern Norway Regional Health Authority (postdoctoral grants and PhD grant) and Diakonhjemmet Hospital.

Authors’ contributions

All authors have made substantial contributions to the conception and design of the study. SWS drafted the manuscript, and all co-authors have read and revised the manuscript. All authors have approved the final manuscript and have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Acknowledgements
Many people have contributed to the study design and implementation of the NOR-DRUM trial. We thank the patient representatives in the study group; Jon Hagfors, Bjørn Gulbrandsen and Ragnar Akre-Aas. We thank Knut Lundin and the scientific advisory board; Josef Smolen, Alejandro C. Balsa Geert D´Haens, Jørn Brynskov and Diamant Thacifor their contributions to the protocol. We thank all study-personnel involved at the clinical departments and Rolf Klaasen, Jakob Katkjær and the other staff at the Department of Medical Biochemistry at Oslo University Hospital Radiumhospitalet. We are grateful to Cecilie Moe, Bjørn Solvang, Nina Flatner, Trond Smedsrud, Marius Eid and Anja Bye for the clinical research support and monitoring during the study.

References

1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanss J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2005;353(23):2462-76.

2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (London, England). 1999;354(9194):1932-9.

3. Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis and rheumatism. 2006;54(5):1646-52.

4. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Annals of the rheumatic diseases. 2005;64(8):1150-7.

5. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and
safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (London, England). 2001;357(9271):1842-7.

6. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2004;2(7):542-53.

7. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. The American journal of gastroenterology. 2011;106(4):685-98.

8. Fisher MD, Watson C, Fox KM, Chen YW, Gandra SR. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Current medical research and opinion. 2013;29(5):561-8.

9. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Annals of the rheumatic diseases. 2013;72(12):1947-55.

10. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. The American journal of gastroenterology. 2013;108(1):40-7; quiz 8.

11. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med. 2013;173(15):1416-28.

12. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Annals of the rheumatic diseases. 2013;72(10):1605-12.
13. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Annals of the rheumatic diseases. 2013;72(10):1613-20.

14. Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2015.

15. Blom M, Kievit W, Kuper HH, Jansen TL, Visser H, den Broeder AA, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken). 2010;62(9):1335-41.

16. Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, et al. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose. Semin Arthritis Rheum. 2013;43(2):144-51.

17. Garces S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Annals of the rheumatic diseases. 2014;73(6):1138-43.

18. Dannepond C, Maruani A, Machet L, Ternant D, Paintaud G, Samimi M. Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review. Acta Derm Venereol. 2015;95(4):401-6.

19. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis and rheumatism.
20. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19(5):478-87.

21. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis and rheumatism. 2006;54(3):711-5.

22. Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2015;27(3):242-8.

23. Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296-307.e5.

24. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease. Gastroenterology. 2015.

25. Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721-7.

26. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2014.

27. Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-
results from a multicenter prospective randomized controlled trial and its post hoc analysis. Journal of gastroenterology. 2016;51(3):241-51.

28. Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert opinion on biological therapy. 2016;16(10):1277-90.

29. Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therapeutic advances in gastroenterology. 2016;9(4):548-59.

30. Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflammatory bowel diseases. 2016;22(8):1999-2015.

31. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the rheumatic diseases. 2017;76(6):960-77.

32. D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018;154(5):1343-51.e1.

33. Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet (London, England). 2017;389(10086):2304-16.

34. Goll GL, Jorgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. Journal of internal medicine.
2019.

35. Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, et al. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2016;14(4):543-9.

36. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism. 2002;46(6):1451-9.

37. Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Alimentary pharmacology & therapeutics. 2011;33(3):349-57.

38. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflammatory bowel diseases. 2012;18(11):2026-33.

Tables

Table 1 Eligibility criteria

Inclusion criteria

NOR-DRUM A

All of the following conditions must apply to the prospective patient at screening;
1. A clinical diagnosis of one of the following; RA, SpA, PsA*, UC, CD or Ps
2. Male or non-pregnant female
3. ≥18 and < 75 years of age at screening
4. A clinical indication to start INX
5. Patient not in remission according to diagnosis-specific disease activity scores
6. Patient capable of understanding and signing an informed consent form

*PsA with predominantly axial manifestations should be included and assessed as SpA

NOR-DRUM B

All of the following conditions must apply to the prospective patient at screening;
1. A clinical diagnosis of one of the following; RA, SpA, PsA*, UC, CD or Ps
2. Male or non-pregnant female
3. ≥18 and < 75 years of age at screening
4. On maintenance therapy with INX for a minimum of 30 weeks and a maximum of 3 years
5. A clinical indication for further INX treatment
6. Patient capable of understanding and signing an informed consent form

*PsA with predominantly axial manifestations should be included and assessed as SpA

Exclusion Criteria

NOR-DRUM A

A patient will be excluded from the study if they meet any of the following criteria:
1. Major co-morbidities, such as previous malignancies within the last 5 years, severe diabetes mellitus, severe infecti hypertension, severe cardiovascular disease, severe respiratory diseases, demyelinating disease, significant chronic syndrome, laboratory abnormalities/significant renal or hepatic disease and/or other diseases or conditions where tr either found contra-indicated by the clinician or which make adherence to the protocol difficult
2. A positive screening for tuberculosis or viral hepatitis
3. Inadequate birth control, pregnancy or patient considering becoming pregnant during the study period
4. Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which m
the study protocol difficult

5. Prior use of INX within the last 6 months

6. For patients with UC and CD: functional colostomy or ileostomy or extensive colonic resection with less than 25 cm situ

NOR-DRUM B

A patient will be excluded from the study if they meet any of the following criteria:

1. Major co-morbidities, such as previous malignancies within the last 5 years, severe diabetes mellitus, severe infective hypertension, severe cardiovascular disease, severe respiratory diseases, demyelinating disease, significant chronic syndrome, laboratory abnormalities/significant renal or hepatic disease and/or other diseases or conditions where treatment with INX is contra-indicated by the clinician or which make adherence to the protocol difficult

2. Inadequate birth control, pregnancy or patient considering becoming pregnant during the study period

3. Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which make adherence to the study protocol difficult

4. For patients with UC and CD: functional colostomy or ileostomy. Extensive colonic resection with less than 25 cm situ.

Abbreviations: CD: Crohn’s disease; INX: Infliximab; Ps: Psoriasis; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; SpA: Spondyloarthritis; UC: Ulcerative colitis

Table 2 Definition of primary outcomes
| Disease | Disease activity scoring tool | Value defining remission | Values defining disease worsening |
|---------|------------------------------|--------------------------|----------------------------------|
| RA      | Disease Activity Score using 28 joint (DAS 28) | <2.6                     |                                  |
| PsA     | Disease Activity Score using 28 joint (DAS 28) | <2.6                     |                                  |
| SpA     | Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP) | <1.3                     |                                  |
| CD      | Harvey-Bradshaw Index (HBI) score | ≤4                       |                                  |
| UC      | Partial Mayo score | ≤2 with no sub scores >1 |                                  |
| Ps      | Psoriasis Area and Severity Index (PASI) | ≤4                       |                                  |

**Abbreviations:** CD: Crohn’s disease; Ps: Psoriasis; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; SpA: Spondyloarthritis; UC: Ulcerative colitis

**Figures**
Overview of study design NOR-DRUM A and NOR-DRUM B. Abbreviations: INX: Infliximab; NOR-DRUM: Norwegian Drug Monitoring; TDM: Therapeutic drug monitoring.

**Figure 1**

| TIMEPOINT | Study period | Visits* (weeks) |
|-----------|--------------|----------------|
| TIMEPOINT | ENROLMENT:   | 0              |
|           | Eligibility screen | X              |
|           | Informed consent  | X              |
|           | Allocation      | X              |
|           | INTERVENTIONS:  |                |
|           | Intervention group (TDM) |            |
|           | Control group (Standard care) | |
|           | ASSESSMENTS:   |                |
|           | Demographics    | X              |
|           | Medical history  | X              |
|           | Comorbidities    |                |
| Comorbidities                              |   |   |   |   |   |
|-------------------------------------------|---|---|---|---|---|
| Physical Examination                      |   | x |   |   |   |
| Body weight                               |   |   |   |   | x |
| Pregnancy test                            | x |   |   |   |   |
| Vital signs                                |   | x | x | x | x |
| Laboratory samples\(^1\)                  |   | x | x | x | x |
| Biobank samples\(^2\)                     |   | x | x | x | x |
| Patient reported outcomes\(^3\)           |   | x | x | x | x |
| Assessments of disease activity\(^4\)     |   | x | x | x | x |
| Adverse event                             |   | x | x | x | x |
| Concomitant medication                    |   | x | x | x | x |
| Clinical evaluation by investigator       | x |   |   |   |   |
| Evaluation of efficacy                    |   |   |   |   | x |
| Treatment administration                  |   | x | x | x | x |
| Establishing dose and inf. interval        |   | x | x | x | x |

**Figure 2**

Schedule of enrolment, interventions, and assessments NOR-DRUM A. 1.

Laboratory samples: hemoglobin, white blood cells with differentials, platelet counts, ALT, albumin, creatinine, CRP, ESR, fecal calprotectin (IBD only) 2.

Biobank samples: serum and full blood at baseline, serum at following visits 3.

Patient reported outcomes: patient global assessment of disease activity (NRS), EQ-5D, SF-36, WPAI-GH, RA: M-HAQ, RAID, PsA: M-HAQ, PsAID, DLQI, SpA: M-HAQ, BASDAI, UC and CD: IBDQ, Psoriasis: DLQI 4. Assessments of disease activity: Nurse/investigator global assessment of disease activity (VAS), RA: DAS28, CDAI,
SDAI, PsA: DAS28, DAPSA, SpA: ASDAS, UC: Partial Mayo score, CD: HBI, Psoriasis:

PASI Abbreviations: ALT: Alanine aminotransferase; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CD: Crohn’s disease; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Score using 28 joints; DLQI: Dermatology Life Quality Index; ESR: Erythrocyte Sedimentation Rate; HBI: Harvey-Bradshaw Index;

IBD: Inflammatory bowel diseases; IBDQ: Inflammatory Bowel Disease Questionnaire; INX; Infliximab; MHAQ: Modified Health Assessment Questionnaire; PASI: Psoriasis Area and Severity Index; PMS: Partial Mayo Score; Ps: Psoriasis;

PsA: Psoriatic arthritis; PsAID: Psoriatic Arthritis Impact of Disease; SDAI: Simplified Disease Activity Index; RA: Rheumatoid arthritis; RAID: Rheumatoid Arthritis Impact of Disease; SF-36: Short Form Health Survey; SpA: Spondyloarthritis; UC: Ulcerative colitis; VAS: Visual analogue scale

| Study period | Enrolment | Allocation | Visits* (weeks) |
|--------------|-----------|------------|-----------------|
| TIMEPOINT    | 0         | 0          | 0-52*           |
|              |           |            | 52              |

**Enrolment:**
- Eligibility screen: X
- Informed consent: X
- Allocation: X

**Interventions:**
- Intervention group (TDM)
- Control group (Standard care)

**Assessments:**
- Demographics: Y
| Medical history |  |  |  |
|-----------------|---|---|---|
| Comorbidities   |  | x | x |
| Physical        |  |  |  |
| Examination     |  |  |  |
| Body weight     |  | x | x |
| Pregnancy test  |  | x |  |
| Vital signs     |  | x | x |
| Laboratory      | ^ |  |  |
| samples\(^1\)   |  | x | x |
| Biobank samples\(^2\) |  | x | x |
| Patient reported| ^ |  |  |
| outcomes\(^3\)  |  | x | x |
| Assessments     |  | x | x |
| of disease      | ^ |  |  |
| activity\(^4\)  |  | x | x |
| Adverse         |  |  | x |
| event           |  |  |  |
| Concomitant     |  | x | x |
| medication      |  |  |  |
| Evaluation      |  |  | x |
| of disease      |  |  |  |
| worsening       |  |  |  |
| Treatment       |  |  | x |
| administration  |  |  |  |
| Establishing    |  |  | x |
| dose and        |  |  |  |
| interval        |  |  | x |

**Figure 3**

Schedule of enrolment, interventions, and assessments NOR-DRUM B. 1.

Laboratory samples: hemoglobin, white blood cells with differentials, platelet counts, ALT, albumin, creatinine, CRP, ESR, fecal calprotectin (IBD only) 2.

Biobank samples: serum and full blood at baseline, serum at following visits 3.

Patient reported outcomes: patient global assessment of disease activity (NRS), EQ-5D, SF-36, WPAI-GH, RA: M-HAQ, RAID, PsA: M-HAQ, PsAID, DLQI, SpA: M-HAQ,
BASDAI, UC and CD: IBDQ, Psoriasis: DLQI 4. Assessments of disease activity: Nurse/investigator global assessment of disease activity (VAS), RA: DAS28, CDAI, SDAI, PsA: DAS28, DAPSA, SpA: ASDAS, UC: Partial Mayo score, CD: HBI, Psoriasis: PASI Abbreviations: ALT: Alanine aminotransferase; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CD: Crohn’s disease; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Score using 28 joints; DLQI: Dermatology Life Quality Index; ESR: Erythrocyte Sedimentation Rate; HBI: Harvey-Bradshaw Index; IBD: Inflammatory bowel diseases; IBDQ: Inflammatory Bowel Disease Questionnaire; INX: Infliximab; MHAQ: Modified Health Assessment Questionnaire; PASI: Psoriasis Area and Severity Index; PMS: Partial Mayo Score; Ps: Psoriasis; PsA: Psoriatic arthritis; PsAID: Psoriatic Arthritis Impact of Disease; SDAI: Simplified Disease Activity Index; RA: Rheumatoid arthritis; RAID: Rheumatoid Arthritis Impact of Disease; SF-36: Short Form Health Survey; SpA: Spondyloarthritis; UC: Ulcerative colitis; VAS: Visual analogue scale
Figure 4

Algorithm for INX administration in NOR-DRUM A (Visits ≤ week 14), intervention group. Abbreviations: ADAb: Anti-drug antibody(ies); ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CD: Crohn’s disease; DAS28: Disease Activity Score using 28 joints; HBI: Harvey-Bradshaw Index; INX: Infliximab; PASI: Psoriasis Area and Severity Index; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; SpA: Spondyloarthritis; UC: Ulcerative colitis

### Table

| Serum INX level (μg/ml) | Infusions up to week 14 | The week 14 visit |
|-------------------------|-------------------------|-------------------|
| <20.0 at infusion 2     | <15.0 at infusion 3     | <3.0              |
| <5 at following infusions up to the week 14 visit | ≥15.0 at infusion 3 | ≥3.0              |
| Increase* dose if no ADAb or low level ADAb (<50 μg/L) | No action | No action |
| or Switch therapy if high levels of ADAb (>50 μg/L) | Within target range, continue with the same dose and dosing interval | Same strategy for improvement and no improvement: |
| If possible to another TNFi | | Increase* dose if no ADAb or low level ADAb (<50 μg/L) |
| | | or Switch therapy if high levels of ADAb (>50 μg/L) |
| | | If possible to another TNFi |

**Guideline for dose increase**

Increase the dose by decreasing the dose interval by 2 weeks to a minimum of 4 weeks (except for the interval between infusion 1-2 and 2-3 where the interval can be minimum 2 weeks)

**Definition of improvement:**
- RA and PsA: A decrease in DAS 28 >1.2
- SpA: A decrease in ASDAS >1.1
- UC: A decrease in partial Mayo score of ≥ 3 points or a partial Mayo score of 0
- CD: A decrease in HBI with ≥ 4 points
- PsA: Achieved PASI 50

For all diseases: An investigator and patient consensus on improvement despite not formally fulfilling improvement definition.
| Serum INX level (µg/ml) | ≤2.0                      | 2.1 – 2.9 | 3.0 – 8.0 | 8.1 – 10.0 | >10.0 |
|-------------------------|--------------------------|-----------|-----------|------------|-------|
| **Action**              | Increase dose if no ADAAb or low level ADAAb (<50 µg/l) or Switch therapy if high levels of ADAAb (>50 µg/l) if possible to another INX | Consider increasing dose | No action | Consider decreasing dose | Decrease dose |
| **Guideline for action**| Increase the dose preferably by increasing the given dose by 2-2.5 mg/kg to a maximum dose of 10 mg/kg or by decreasing the dose interval by 2 weeks to a minimum of 4 weeks | Consider (based on clinical judgement and the patients factors given below*) increasing the dose preferably by increasing the given dose by 2-2.5 mg/kg to a maximum dose of 10 mg/kg or by decreasing the dose interval by 2 weeks to a minimum of 4 weeks | Within target range. Continue with the same dose and dosing interval | Consider (based on clinical judgement and the patients factors given below*) to decrease the dose preferably by increasing the dose interval by 2 weeks to a maximum of 10 weeks or by decreasing the given dose by 2-2.5 mg/kg | Decrease the dose preferably by increasing the dose interval by 2 weeks to a maximum of 10 weeks or by decreasing the given dose by 2-2.5 mg/kg |

*Patient factors to be considered when making the treatment decisions in the yellow zones: Disease activity and trend in disease activity, the trend of the trough level over time, previous drug interval changes, availability of alternative drug, diagnosis (RA patients are expected to have lower trough levels due to lower recommended dosing)*

### Figure 5

Algorithm for INX administration NOR-DRUM A (Visits ≥ 14 weeks) and NOR-DRUM B, intervention group. Abbreviations: ADAAb: Anti-drug antibody (ies); ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CD: Crohn’s disease; DAS28: Disease Activity Score using 28 joints; HBI: Harvey-Bradshaw Index; INX: Infliximab; PASI: Psoriasis Area and Severity Index; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; SpA: Spondyloarthritis UC: Ulcerative colitis

### Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

SPIRIT-Checklist 1.0.doc